Alvotech to Supply High-Concentration Adalimumab Biosimilar to Quallent for U.S. Market
Alvotech will manufacture its high-concentration, interchangeable adalimumab biosimilar for Quallent Pharmaceuticals in the U.S. The agreement aligns with Alvotech's existing U.S. commercialization partnership with Teva Pharmaceuticals.
Biotechnology firm Alvotech has finalized a manufacturing agreement with Quallent Pharmaceuticals to supply its high-concentration, interchangeable biosimilar of adalimumab for the U.S. market. The drug, approved by the FDA, is a citrate-free alternative to AbbVie's Humira®.
This agreement marks a significant step in bringing Alvotech's biosimilar to patients. The FDA granted the high-concentration formulation interchangeability status, meaning it can be substituted for Humira® at the pharmacy. This is particularly relevant as nearly 88 percent of U.S. adalimumab prescriptions are for the high-concentration version.
The manufacturing deal operates in conjunction with Alvotech's existing U.S. commercialization agreement with Teva Pharmaceuticals. Teva will handle the U.S. launch and distribution of the biosimilar, leveraging its established sales and marketing infrastructure. Quallent will distribute the Alvotech-manufactured product under its own private label.
Alvotech and Teva have partnered since 2020, focusing on expanding patient access to affordable biologic medicines. This latest agreement is part of their ongoing strategy to commercialize multiple biosimilar candidates in the United States.